EarningsQ2 2026 Earnings Report
DE:2Y3 Q2 2026 EPS Results
Actual EPS-€0.59
Consensus EPS-€0.60
Beat/MissBeat by +<€0.01
One Year Ago EPS-€1.78
DE:2Y3 Q2 2026 Revenue Results
Actual Revenue€7.29M
Expected Revenue€6.74M
Beat/MissBeat by +€552.40K
YoY Revenue Growth+21.36%
Earnings Announcement Details
QuarterQ2 2026
Date08/10/2026
TimeAfter Close
Conference CallMonday, August 10, 2026
DE:2Y3 Upcoming Earnings
BioNano Genomics's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:2Y3 Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong execution on key commercial and clinical fronts: double-digit revenue growth, record flow-cell sales, a shift to higher-margin consumable revenue, improved gross margins (53%), significant clinical publications validating OGM, and the retirement of convertible debt. These positives were tempered by operational constraints — notably manufacturing capacity and backorders — a modest cash balance with runway into early 2027, and a YoY decline in software revenue. Management raised the low end of full-year guidance but remained cautious on the upside until supply constraints are resolved.Company Guidance
Revenue Growth and Beat
Total revenue of $8.2 million in Q2 2026, up 21% year-over-year, and above prior guidance of $7.5M–$7.8M.
Record Consumable Demand and Flow Cells Sold
Sold a record 9.22 thousand nanochannel array flow cells in Q2, up 27% year-over-year; consumable revenue was $4.3 million, up 30% year-over-year, driven primarily by increased clinical adoption and higher utilization at existing sites.
Recurring Revenue Mix Shift
Other revenue (instruments & services) grew to $2.5 million, up 38% year-over-year, while the business mix is tilting toward higher-margin recurring consumables and software.
Installed Base and Utilization Expansion
Installed base reached 397 OGM systems worldwide, up 5% year-over-year, with meaningful increases in flow-cell utilization among routine clinical users (24% YoY flow cells to existing customers after excluding system-tied sales).
Gross Margin Improvement
Adjusted gross margin reached 53% in Q2 2026 (highest quarterly gross margin to date), up from ~52% in Q2 2025 and materially improved from high-20% levels in 2023.
Clinical Evidence and Publication Momentum
Significant clinical publications: largest OGM T-ALL study (91 cases) showing OGM detected genomic abnormalities in 97.8% vs 55% by karyotype and provided clinically relevant information in ~70% of cases; 13 reproductive/prenatal studies covering 730 subjects; OGM presentations at ESHG increased 67% YoY across 17 countries.
Product and Commercial Progress
Positive customer feedback on software/compute upgrades (VIA) enabling menu expansion and throughput increases; Ionic sample-prep expansion targeting OGM interface and expected launch in Q4 2026, anticipated to drive incremental consumable revenue.
Balance Sheet & Financial Milestones
Fully retired outstanding senior secured convertible debt in Q2 and ended the quarter with $10.4 million in cash and equivalents; management raised the low end of FY2026 revenue guidance to $31M–$33M (9%–16% growth over 2025) and initiated Q3 guidance of $8.2M–$8.6M (11%–16% YoY growth).
DE:2Y3 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed